MX367624B - Uso combinado de un antagonista del receptor del factor de crecimiento similar a la insulina y un antagonista del receptor de andrógenos para tratar la neoplasia prostática. - Google Patents
Uso combinado de un antagonista del receptor del factor de crecimiento similar a la insulina y un antagonista del receptor de andrógenos para tratar la neoplasia prostática.Info
- Publication number
- MX367624B MX367624B MX2015011579A MX2015011579A MX367624B MX 367624 B MX367624 B MX 367624B MX 2015011579 A MX2015011579 A MX 2015011579A MX 2015011579 A MX2015011579 A MX 2015011579A MX 367624 B MX367624 B MX 367624B
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- receptor antagonist
- treatment
- neoplasia
- neoplasia treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un antagonista de los receptores con factor de crecimiento similar al de la insulina (IGF) para uso en el tratamiento de la neoplasia prostática que incluye la hiperplasia prostática benigna (HPB), cáncer de próstata, y particularmente CRPC, en el que el antagonista se utiliza en combinación con un antagonista de los receptores andrógenos. Una modalidad de la invención es aquella en donde el antagonista del receptor de los andrógenos es la enzalutamida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13158228 | 2013-03-07 | ||
PCT/EP2014/054300 WO2014135611A1 (en) | 2013-03-07 | 2014-03-06 | Combination therapy for neoplasia treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015011579A MX2015011579A (es) | 2015-12-09 |
MX367624B true MX367624B (es) | 2019-08-29 |
Family
ID=47827067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011579A MX367624B (es) | 2013-03-07 | 2014-03-06 | Uso combinado de un antagonista del receptor del factor de crecimiento similar a la insulina y un antagonista del receptor de andrógenos para tratar la neoplasia prostática. |
Country Status (16)
Country | Link |
---|---|
US (2) | US20140255413A1 (es) |
EP (1) | EP2964256B1 (es) |
JP (1) | JP6532828B2 (es) |
KR (1) | KR20150123859A (es) |
CN (1) | CN105007942A (es) |
AR (1) | AR095041A1 (es) |
AU (1) | AU2014224608B2 (es) |
BR (1) | BR112015020943A2 (es) |
CA (1) | CA2903645A1 (es) |
CL (1) | CL2015002455A1 (es) |
EA (1) | EA034884B1 (es) |
IL (1) | IL240599A0 (es) |
MX (1) | MX367624B (es) |
PH (1) | PH12015501852A1 (es) |
UY (1) | UY35371A (es) |
WO (1) | WO2014135611A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA029178B1 (ru) | 2008-12-12 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
EP3030249B1 (en) | 2013-08-07 | 2019-12-25 | Rigshospitalet, Copenhagen University Hospital | Antibodies, compounds and derivatives thereof for use in the treatment of male infertility |
MX2017003406A (es) | 2014-09-17 | 2017-06-19 | Merck Patent Gmbh | Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea. |
MX2017003015A (es) | 2014-09-17 | 2017-05-23 | Merck Patent Gmbh | Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos. |
WO2016113572A1 (en) * | 2015-01-16 | 2016-07-21 | The University Of Liverpool | Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy |
US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
WO2017055291A1 (en) | 2015-09-28 | 2017-04-06 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
CN108114271B (zh) * | 2016-11-29 | 2021-07-02 | 中国科学院上海营养与健康研究所 | 含胰岛素样生长因子-2的药物组合物及其应用 |
CN111148534A (zh) * | 2017-09-29 | 2020-05-12 | 勃林格殷格翰国际有限公司 | 抗igf和抗pd-1抗癌组合疗法 |
WO2019184952A1 (en) * | 2018-03-29 | 2019-10-03 | Hinova Pharmaceuticals Inc. | Deuterated imidazolidinedione compounds and their uses |
US20210332392A1 (en) * | 2020-04-24 | 2021-10-28 | Lawrence Livermore National Security, Llc | Compositions and methods of use thereof for scandium separation from rare earth containing material |
CN115721629B (zh) * | 2022-10-31 | 2024-02-20 | 西安交通大学 | 多西他赛与恩杂鲁胺联合用药pH响应型铁-铜磁性纳米载药系统及其制备和应用 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
ATE95236T1 (de) | 1983-04-25 | 1993-10-15 | Chiron Corp | Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren. |
WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
AU1232188A (en) | 1987-05-29 | 1988-12-01 | Mallinckrodt, Inc. | Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i |
DE68908175T2 (de) | 1988-05-27 | 1994-03-03 | Centocor Inc | Gefriergetrocknete formulierung für antikörperprodukte. |
DE68927854T2 (de) | 1988-06-30 | 1997-10-16 | Hope City | Insulinomimetrische eigenschaften und insulin-rezeptor-bindestellen-peptide |
CA2058041A1 (en) | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
US6193969B1 (en) | 1993-06-03 | 2001-02-27 | Protherics Inc. | Antibody fragments in therapy |
EP0700994A1 (en) | 1994-03-23 | 1996-03-13 | Japan Clinical Laboratories | Anti-igf-i monoclonal antibody |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
DE69834828T2 (de) | 1997-11-27 | 2007-01-04 | Commonwealth Scientific And Industrial Research Organisation | Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) |
EP1185559A2 (en) | 1999-04-28 | 2002-03-13 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
PE20020801A1 (es) | 2001-01-05 | 2002-09-06 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
RU2420537C2 (ru) | 2001-01-17 | 2011-06-10 | Трабьон Фармасьютикалз Инк. | Слитые белки связывающий домен-иммуноглобулин |
WO2003002609A2 (en) | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
PT1461359E (pt) | 2002-01-18 | 2007-06-29 | Pf Medicament | Anticorpos anti-igf-ir e suas aplicações |
ATE444972T1 (de) | 2002-04-30 | 2009-10-15 | Kyowa Hakko Kirin Co Ltd | ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR |
JP2003310275A (ja) | 2002-04-30 | 2003-11-05 | Kyowa Hakko Kogyo Co Ltd | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
JP4563171B2 (ja) | 2002-05-24 | 2010-10-13 | シェーリング コーポレイション | 中和ヒト抗igfr抗体 |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
CN1678634A (zh) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
US20030138430A1 (en) | 2002-09-20 | 2003-07-24 | Stimmel Julie Beth | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
NZ582210A (en) | 2003-02-13 | 2011-04-29 | Pfizer Prod Inc | Uses of anti-insulin-like growth factor I receptor antibodies |
CA2518980A1 (en) | 2003-03-14 | 2004-09-30 | Pharmacia Corporation | Antibodies to igf-i receptor for the treatment of cancers |
JP2007535895A (ja) | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−1受容体に対する完全ヒト抗体 |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
EP1661582A1 (en) | 2003-08-21 | 2006-05-31 | Kyowa Hakko Kogyo Co., Ltd. | Cancer metastasis inhibitor |
ATE492562T1 (de) | 2003-09-24 | 2011-01-15 | Kyowa Hakko Kirin Co Ltd | Rekombinanter antikörper gegen humanen insulin- like growth factor |
CA2540133A1 (en) | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | Drugs for treating cancer |
WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
KR20080019733A (ko) * | 2004-07-16 | 2008-03-04 | 화이자 프로덕츠 인코포레이티드 | 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료 |
MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
KR101472250B1 (ko) | 2005-10-12 | 2014-12-11 | 모르포시스 아게 | 인간 cd38에 특이적인 완전 인간 hucal gold-유도 치료 항체들의 생성 및 프로파일링 |
ES2385054T3 (es) | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
AU2007212447B2 (en) | 2006-02-03 | 2013-02-21 | Imclone Llc | IGF-IR antagonists as adjuvants for treatment of prostate cancer |
EP1999149A4 (en) | 2006-03-28 | 2010-01-20 | Biogen Idec Inc | ANTI-IGF-1R ANTIBODIES AND USES THEREOF |
KR20090029184A (ko) | 2006-04-07 | 2009-03-20 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항체 조성물 및 신생물성 질병의 치료 방법 |
US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
RU2429486C2 (ru) | 2006-06-02 | 2011-09-20 | Пфайзер Продактс Инк. | Анализ циркулирующих опухолевых клеток |
EP2032989B2 (en) | 2006-06-30 | 2015-10-28 | Merck Sharp & Dohme Corp. | Igfbp2 biomarker |
US7749966B2 (en) | 2006-12-21 | 2010-07-06 | Boston Biomedical Research Institute | Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity |
WO2008079849A2 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
GB0702888D0 (en) | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
JP2010520204A (ja) | 2007-03-02 | 2010-06-10 | アムジェン インコーポレイテッド | 腫瘍疾患を治療するための方法および組成物 |
WO2008115470A2 (en) | 2007-03-16 | 2008-09-25 | East Carolina University | Hox-gene expression as a biomarker for igf-1r therapeutics |
BRPI0809112A2 (pt) | 2007-03-22 | 2014-08-26 | Imclone Llc | Formulações estáveis de anticorpos |
EP2145021A2 (en) | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
US8178091B2 (en) | 2007-05-21 | 2012-05-15 | University Of Washington | Compositions and methods for the treatment of respiratory disorders |
WO2008152422A2 (en) | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
WO2009006336A1 (en) | 2007-06-28 | 2009-01-08 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
US20110014117A1 (en) | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
AU2008282863A1 (en) | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
AU2008281801A1 (en) | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
WO2009019117A1 (en) | 2007-08-03 | 2009-02-12 | Affibody Ab | Igf-1r binding polypeptides and their use |
EP2185726B1 (en) | 2007-08-06 | 2014-01-08 | Orion Genomics, LLC | Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene |
WO2009032782A2 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
EP2190480A4 (en) | 2007-08-28 | 2013-01-23 | Biogen Idec Inc | ANTI-IGR-1R ANTIBODIES AND ITS USES |
WO2009039457A1 (en) | 2007-09-19 | 2009-03-26 | The Trustees Of Boston University | Identification of novel pathways for drug development for lung disease |
US7939272B2 (en) | 2007-10-03 | 2011-05-10 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2009045389A2 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
TWI580694B (zh) * | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-vegf抗體 |
US20110091524A1 (en) | 2007-12-18 | 2011-04-21 | Yan Wang | Biomarkers for sensitivity to anti-igf1r therapy |
US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
CN102065895A (zh) | 2008-04-11 | 2011-05-18 | 比奥根艾迪克Ma公司 | 抗-igf-1r抗体和其它化合物的治疗联合 |
MX2010012064A (es) | 2008-05-05 | 2010-12-06 | Schering Corp | Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer. |
EP2296703A4 (en) | 2008-05-09 | 2012-09-05 | Dyax Corp | IGF-II / IGF-IIE BINDING PROTEINS |
UY31861A (es) | 2008-06-03 | 2010-01-05 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
EP2342318A1 (en) | 2008-09-26 | 2011-07-13 | Schering Corporation | High titer antibody production |
CA2736408A1 (en) | 2008-09-26 | 2010-04-01 | Roche Glycart Ag | Bispecific anti-egfr/anti-igf-1r antibodies |
CA2740440A1 (en) | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis |
JP2012506238A (ja) | 2008-10-20 | 2012-03-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | インスリン様増殖因子−1受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー |
CN102232087A (zh) | 2008-11-10 | 2011-11-02 | 诺瓦提斯公司 | 修饰的人igf-1/e肽的抗体 |
NZ592644A (en) | 2008-11-28 | 2013-09-27 | Abbott Lab | Stable antibody compositions and methods for stabilizing same |
EA029178B1 (ru) * | 2008-12-12 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Антитела против инсулиноподобных факторов роста, молекула днк, вектор, клетка-хозяин, предназначенные для получения этого антитела, способ его получения и применение |
WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
AU2009329911A1 (en) | 2008-12-23 | 2011-07-21 | Salk Institute For Biological Studies | Method of treating neurodegenerative disease |
CN102458466A (zh) | 2009-04-16 | 2012-05-16 | 默沙东公司 | 使用抗-egfr剂和igf-1r特异性的抑制剂的组合治疗 |
WO2011057064A1 (en) * | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
WO2013000148A1 (en) * | 2011-06-30 | 2013-01-03 | Renesas Mobile Corporation | Method and apparatus for improved wireless sensor network interactions |
EP2852685A1 (en) * | 2012-03-30 | 2015-04-01 | Merck Sharp & Dohme Corp. | Igf1 biomarker for igf1r inhibitor therapy |
WO2013169611A1 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Compositions and methods for treating breast cancer |
JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
RS59649B1 (sr) | 2014-01-24 | 2020-01-31 | Boehringer Ingelheim Int | Lečenje raka korišćenjem receptora antagoniste faktora rasta sličan insulinu (igf) u kombinaciji sa eksemestanom i everolimusom |
WO2017055291A1 (en) | 2015-09-28 | 2017-04-06 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
-
2014
- 2014-03-04 US US14/196,231 patent/US20140255413A1/en not_active Abandoned
- 2014-03-06 CA CA2903645A patent/CA2903645A1/en not_active Abandoned
- 2014-03-06 BR BR112015020943A patent/BR112015020943A2/pt not_active IP Right Cessation
- 2014-03-06 JP JP2015560682A patent/JP6532828B2/ja not_active Expired - Fee Related
- 2014-03-06 CN CN201480010868.8A patent/CN105007942A/zh active Pending
- 2014-03-06 WO PCT/EP2014/054300 patent/WO2014135611A1/en active Application Filing
- 2014-03-06 EP EP14709911.3A patent/EP2964256B1/en active Active
- 2014-03-06 AR ARP140100739A patent/AR095041A1/es unknown
- 2014-03-06 EA EA201500906A patent/EA034884B1/ru not_active IP Right Cessation
- 2014-03-06 KR KR1020157026215A patent/KR20150123859A/ko not_active Application Discontinuation
- 2014-03-06 AU AU2014224608A patent/AU2014224608B2/en not_active Ceased
- 2014-03-06 MX MX2015011579A patent/MX367624B/es active IP Right Grant
- 2014-03-07 UY UY0001035371A patent/UY35371A/es unknown
-
2015
- 2015-08-17 IL IL240599A patent/IL240599A0/en unknown
- 2015-08-24 PH PH12015501852A patent/PH12015501852A1/en unknown
- 2015-09-02 CL CL2015002455A patent/CL2015002455A1/es unknown
- 2015-11-19 US US14/946,067 patent/US10377828B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PH12015501852B1 (en) | 2016-01-18 |
AU2014224608A1 (en) | 2015-09-10 |
WO2014135611A1 (en) | 2014-09-12 |
AU2014224608B2 (en) | 2018-08-09 |
JP2016511265A (ja) | 2016-04-14 |
US10377828B2 (en) | 2019-08-13 |
PH12015501852A1 (en) | 2016-01-18 |
MX2015011579A (es) | 2015-12-09 |
KR20150123859A (ko) | 2015-11-04 |
AR095041A1 (es) | 2015-09-16 |
EA034884B1 (ru) | 2020-04-01 |
IL240599A0 (en) | 2015-09-24 |
BR112015020943A2 (pt) | 2017-10-10 |
EP2964256B1 (en) | 2020-11-11 |
JP6532828B2 (ja) | 2019-06-19 |
CL2015002455A1 (es) | 2016-05-27 |
CA2903645A1 (en) | 2014-09-12 |
NZ711210A (en) | 2020-11-27 |
EA201500906A1 (ru) | 2016-03-31 |
EP2964256A1 (en) | 2016-01-13 |
US20160199488A1 (en) | 2016-07-14 |
UY35371A (es) | 2014-09-30 |
US20140255413A1 (en) | 2014-09-11 |
CN105007942A (zh) | 2015-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX367624B (es) | Uso combinado de un antagonista del receptor del factor de crecimiento similar a la insulina y un antagonista del receptor de andrógenos para tratar la neoplasia prostática. | |
EP3618914A4 (en) | IMPLANTABLE DEVICES AND TREATMENT METHODS FOR BENIGN PROSTATE HYPERPLASIA (BPH) AND ASSOCIATED LOWER URINARY TRACT SYMPTOMS (LUTS) | |
PH12018502570A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
JO3606B1 (ar) | معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا | |
TW201613647A (en) | Compounds and compositions for treating HER2 positive tumors | |
MX2016007885A (es) | Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20. | |
MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
EP3061459A4 (en) | Composition for treating and preventing benign prostatic hyperplasia | |
PH12015502855A1 (en) | Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations | |
JP2014503537A5 (es) | ||
WO2012018404A3 (en) | Use of her3 binding agents in prostate treatment | |
PH12015502342B1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
MX2023000191A (es) | Metodos de fabricacion y uso de inhibidores de pde9. | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
MX2017006076A (es) | Dianhidrogalactitol junto con radiacion, para tratar carcinoma de pulmón de celulas no pequeñas y glioblastoma multiforme. | |
MX2016009515A (es) | Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados. | |
MX2010004259A (es) | Tratamientos antitumorales mejorados. | |
MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
MX2019011118A (es) | Uso de oleorresina de copaifera en patologias de la prostata. | |
NZ742470A (en) | Combination therapy for cancer | |
PH12018502571A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
CL2009001982A1 (es) | Compuestos derivados de pirrolidin-1-il benzonitrilo; y su uso en el tratamiento del cancer de prostata hormono dependiente mediado por el antagonismo del receptor de androgenos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |